Burden of illness of hepatitis C from a managed care organization perspective

被引:22
作者
Armstrong, EP [1 ]
Charland, SL
机构
[1] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[2] Univ Colorado, Sch Pharm, Denver, CO 80202 USA
[3] Kos Pharmaceut Inc, Denver, CO USA
关键词
cost; hepatitis C; HIV; managed care;
D O I
10.1185/030079904125003485
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The objectives of this study were to: (1) determine the total hepatitis C virus (HCV)related and total healthcare costs (HCV plus other co-morbidities) of patients with HCV in a managed care organization; (2) determine total healthcare costs of HCV patients with and without a human immunodeficiency virus (HIV) infection as a comorbidity. Methods: The study design was a retrospective analysis of a medical and pharmacy claims database of patients diagnosed with HCV in a 325 000 member managed care organization. Patients diagnosed with HCV and 12 months of continuous eligibility in the managed care organization from January 1997 through December 1999 were included in the study. The main outcome measures of the study were the total healthcare costs and HCV-related healthcare costs and the impact of HIV as a co-morbidity on these costs. Results: The study identified 614 patients meeting the inclusion criteria. The study population was 58% male and had a mean age of 46 (10.6) years. In patients receiving Interferon-alpha, their median total healthcare costs exceeded $4600 and the median HCV-related costs exceeded $2470. The total healthcare costs of HCV patients with HIV as a co-morbidity were significantly larger than patients without this comorbidity. Conclusion: HCV represents a very important disease to managed care organizations. Patients with this disease require costly drug therapies and consume significant health care resources. Additional research is needed to more fully characterize future clinical and economic outcomes as new agents become available.
引用
收藏
页码:671 / 679
页数:9
相关论文
共 37 条
  • [1] Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome
    Alter, HJ
    Seeff, LB
    [J]. SEMINARS IN LIVER DISEASE, 2000, 20 (01) : 17 - 35
  • [2] The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
    Alter, MJ
    Kruszon-Moran, D
    Nainan, OV
    McQuillan, GM
    Gao, FX
    Moyer, LA
    Kaslow, RA
    Margolis, HS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) : 556 - 562
  • [3] [Anonymous], 1997, HEPATOLOGY, V26, pS2
  • [4] Modeling therapeutic benefit in the midst of uncertainty - Therapy for hepatitis C
    Bennett, WG
    Pauker, SG
    Davis, GL
    Wong, JB
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (12) : S56 - S62
  • [5] Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C
    Bennett, WG
    Inoue, Y
    Beck, JR
    Wong, JB
    Pauker, SG
    Davis, GL
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) : 855 - +
  • [6] Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C
    Buti, M
    Casado, MA
    Fosbrook, L
    Wong, JB
    Esteban, R
    [J]. JOURNAL OF HEPATOLOGY, 2000, 33 (04) : 651 - 658
  • [7] Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis
    Davis, GL
    Beck, JR
    Farrell, G
    Poynard, T
    [J]. JOURNAL OF VIRAL HEPATITIS, 1998, 5 (05) : 313 - 321
  • [8] Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
    Davis, GL
    Esteban-Mur, R
    Rustgi, V
    Hoefs, J
    Gordon, SC
    Trepo, C
    Shiffman, ML
    Zeuzem, S
    Craxi, A
    Ling, MH
    Albrecht, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) : 1493 - 1499
  • [9] HIGH-LEVEL OF HEPATITIS-C ENDEMICITY IN GABON, EQUATORIAL AFRICA
    DELAPORTE, E
    THIERS, V
    DAZZA, MC
    ROMEO, R
    MLIKACABANNE, N
    APTEL, I
    SCHRIJVERS, D
    BRECHOT, C
    LAROUZE, B
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1993, 87 (06) : 636 - 637
  • [10] INCIDENCE OF HEPATITIS-C VIRUS IN EGYPTIANS
    ELAHMADY, O
    HALIM, AB
    MANSOUR, O
    SALMAN, T
    [J]. JOURNAL OF HEPATOLOGY, 1994, 21 (04) : 687 - 687